Showing 1801-1810 of 2038 results for "".
- Study Shows Highest IOL Prediction Accuracy for Hill-RBF 3.0https://modernod.com/news/study-shows-highest-iol-prediction-accuracy-for-hill-rbf-30/2480856/A recently published study shows that Hill-RBF 3.0 performs better at predicting refractive outcomes in cataract surgery than any of the other formulae assessed, acclording to a Haag-Streit news release. To analyze refractive outcomes in cataract surgery, Dr. Adi Abulafia, and his team
- Kala Pharmaceuticals Announces New Commercial and Medicare Coverage for Eysuvishttps://modernod.com/news/kala-pharmaceuticals-announces-new-commercial-and-medicare-coverage-for-eysuvis/2480834/Kala Pharmaceuticals announced that the largest Pharmacy Benefit Manager in the United States has added Eysuvis (loteprednol etabonate ophthalmic suspension) 0.25% as a covered brand on its commercial formularies, effective May 1, 2022. This adds 28.5 million people to Eysuvis coverage,
- Heidelberg Engineering Presents Various Scientific Innovations at ARVOhttps://modernod.com/news/heidelberg-engineering-presents-various-scientific-innovations-at-arvo/2480819/Heidelberg Engineering showcases its research capabilities at this year’s ARVO congress that takes place in Denver, Colorado, USA, from May 1–4. The team looks forward to reconnecting with the global research community after 2 years of solely virtual ARVO meetings, and to demonstratin
- New Data on Potential of Opus AAV-based Gene Therapies for Rare Inherited Retinal Diseases to be Presented at ARVOhttps://modernod.com/news/new-data-on-potential-of-opus-aav-based-gene-therapies-for-rare-inherited-retinal-diseases-to-be-presented-at-arvo/2480815/Opus Genetics announced that data from two preclinical studies evaluating the potential of its gene therapies OPGx-001 and OPGx-002 to address forms of Leber congenital amaurosis (LCA) due to mutations of LCA5 or RDH12 genes, respectively, will b
- Euclid Vision Announces Acquisition of Visionary Opticshttps://modernod.com/news/euclid-vision-announces-acquisition-of-visionary-optics/2480780/Euclid Vision, formerly Euclid Systems, has anno
- Amydis Appoints Robert N. Weinreb, MD, as First Chair of Scientific Advisory Boardhttps://modernod.com/news/amydis-appoints-robert-n-weinreb-md-as-first-chair-of-scientific-advisory-board/2480742/Amydis announced the appointment of clinician scientist, Robert N. Weinreb, MD, as the First Chair to the Scientific Advisory Board of the company. “Amydis is at the forefront of developing compounds that enable retinal imaging of molecula
- Glaukos Announces Commencement of Phase 2 Corneal Health Clinical Program for Third-Generation iLink Therapyhttps://modernod.com/news/glaukos-announces-commencement-of-phase-2-corneal-health-clinical-program-for-third-generation-ilink-therapy/2480696/Glaukos announced that it has commenced a phase 2 clinical program for its third-generation iLink therapy designed to treat keratoconus. Glaukos’ iLink pharmaceutical platform consists of novel single-use drug formulations that are bio-activa
- Kala Pharmaceuticals Announces Eysuvis Now Covered on UnitedHealthcare Commercial and Cigna Medicarehttps://modernod.com/news/kala-pharmaceuticals-announces-eysuvis-now-covered-on-unitedhealthcare-commercial-and-cigna-medicare/2480681/Kala Pharmaceuticals announced that UnitedHealthcare, one of the largest commercial health care plans in the United States covering approximately 13 million people, has added Eysuvis (loteprednol etabonate ophthalmic suspension) 0.25% as a covered brand on its commercial formularies eff
- 1-800 Contacts Announces New Company Focused on B2B Vision Technologies and Serviceshttps://modernod.com/news/1-800-contacts-announces-new-company-focused-on-b2b-vision-technologies-and-services/2480662/1-800 Contacts recently announced the formation of a standalone business, Luna Solutions, focused on providing technology and services to third parties in the vision space. The company offers 20 integrated technologies and services–ranging from telehealth platforms for n
- Nicox Granted New Patent for NCX 4251 in Japanhttps://modernod.com/news/nicox-granted-new-patent-for-ncx-4251-in-japan/2480657/Nicox SA announced that the Japanese Patent Office has granted a new patent expiring in 2040 covering the company’s product candidate NCX 4251. Patent JP.7021301 covers ophthalmic suspensions comprising a specific form of fluticasone p